echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Roxastat, a targeted Nobel pathway, was approved by the European Commission for listing

    Roxastat, a targeted Nobel pathway, was approved by the European Commission for listing

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Astellas Pharma and FibroGen today announced that the European Commission (EC) has approved the marketing of Evrenzo (roxadustat) for the treatment of adult patients with chronic kidney disease (CKD) related symptomatic anemia


    The global incidence of CKD is 1/10, and 1/5 of the patients suffer from anemia


    Roxastat is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved by the European Union


    This approval follows the positive opinions of the European Medicines Agency (EMA) Committee on Medicines for Human Use (CHMP) and is based on the results of a pivotal Phase 3 R&D project consisting of 8 multi-center and randomized studies


    Reference materials:

    [1] Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.